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Abstract
 
Heat shock proteins (HSPs) like glycoprotein (gp)96 (glucose-regulated protein 94 [grp94]) are
able to induce specific cytotoxic T lymphocyte (CTL) responses against cells from which they
originate. Here, we demonstrate that for CTL activation by gp96-chaperoned peptides, specific
receptor-mediated uptake of gp96 by antigen-presenting cells (APCs) is required. Moreover,
we show that in both humans and mice, only professional APCs like dendritic cells (DCs),
macrophages, and B cells, but not T cells, are able to bind gp96. The binding is saturable and
can be inhibited using unlabeled gp96 molecules. Receptor binding by APCs leads to a rapid
internalization of gp96, which colocalizes with endocytosed major histocompatibility complex
(MHC) class I and class II molecules in endosomal compartments. Incubation of gp96 mole-
cules isolated from cells expressing an adenovirus type 5 E1B epitope with the DC line D1 re-
sults in the activation of E1B-specific CTLs. This CTL activation can be specifically inhibited
by the addition of irrelevant gp96 molecules not associated with E1B peptides. Our results
 
demonstrate that only receptor-mediated endocytosis of gp96 molecules leads to MHC class
 
I–restricted re-presentation of gp96-associated peptides and CTL activation; non–receptor-medi-
ated, nonspecific endocytosis is not able to do so. Thus, we provide evidence on the mecha-
nisms by which gp96 is participating in the cross-presentation of antigens from cellular origin.
Key words: heat shock protein–peptide complex • cross-priming • receptor-mediated 
endocytosis • cytotoxic T lymphocyte activation • dendritic cell
 
Introduction
 
Activation of CTLs with exogenous cell-associated anti-
gens requires efficient uptake and presentation of these an-
tigens by bone marrow–derived APCs. This phenomenon
was first observed by Bevan (1–3) for the induction of
CTLs against minor H antigens. Because the antigens were
expressed in foreign donor cells with different MHC mole-
cules, this process was termed “cross-priming.” Since then,
it has been shown that soluble protein antigens (4, 5), anti-
gens expressed in MHC matched cells (6–8), or antigens
encoded by naked DNA (9) also require uptake and re-pre-
sentation by MHC molecules expressed on the surface of
professional APCs. Therefore, the term “cross-presenta-
tion” was introduced to describe the general re-presenta-
tion of exogenous cell-associated antigens by MHC class I
(6) and MHC class II molecules (10). In addition to CTL
activation, cross-presentation can also lead to the induction
of CTL tolerance (11, 12).
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The nature of the APCs that are able to take up and re-
present cell-associated antigens on MHC class I molecules
remains elusive in vivo. However, in vitro studies suggest
that dendritic cells (DCs)
 
1
 
 (11–13), macrophages (14–16),
or B cells (17) might be involved.
Several pathways for antigen uptake have been described,
ranging from nonspecific mechanisms such as phagocytosis,
pinocytosis, or macropinocytosis (18–23) to specific, recep-
tor-operated mechanisms that include mannose- and scav-
enger-type receptors (22). Depending on the nature of the
antigens, and consequently on the mode of uptake, antigens
might be targeted to different processing compartments and
be able to gain access to different antigen presentation path-
ways. CTL activation can be mediated by macropinocytosis
or phagocytosis of exogenous soluble antigens (24–26).
However, these pathways require high antigen concentra-
tions and might therefore be of limited relevance in provid-
ing a mechanism for cross-presentation in vivo (23).
More recently, apoptotic bodies were shown to be phago-
cytosed by immature DCs, resulting in the activation of
MHC class I–restricted T cells (13, 27). This uptake involves
CD36 and the integrin receptor 
 
a
 
v
 
b
 
5
 
 (28), which explains
the high efficiency.
An additional pathway with potential relevance for
cross-presentation became evident when the induction of
tumor immunity and CTL activation through the injection
of heat shock proteins (HSPs) such as glycoprotein (gp)96,
HSP70, and HSP90 was discovered (for a review, see refer-
ence 29). The specificities of the CTL response were di-
rected against the cells from which the HSPs were isolated.
This can be explained by the association of the HSPs with
peptides of cellular origin. Immune responses against sev-
eral cellular antigens including minor H and tumor and vi-
ral antigens were induced (for a review, see reference 30)
by using as little as 1–2 ng HSP–peptide complex in one
particular case (31). It was postulated that the extremely ef-
ficient MHC presentation of HSP-associated peptides is ac-
complished by the receptor-mediated uptake of HSPs by
professional APCs (32). Recently, binding of HSP70 and
gp96 to a macrophage- and dendritic-like cell line was ob-
served (33). This observation provides a possible explanation
for the high immunogenic potential of HSPs in situations in
which they are injected into mice or released from dying
cells, in that they shuttle antigenic peptides to APCs (32).
Receptor-mediated endocytosis of HSPs by professional
APCs will lead to the accumulation of these peptide chaper-
ones in cells crucially involved in the activation of CTLs.
We therefore decided to characterize the cell popula-
tions involved in receptor-mediated endocytosis of HSPs in
detail, to follow the fate of endocytosed HSPs, and to test
whether or not receptor-mediated endocytosis of HSPs in-
deed results in the re-presentation of HSP-associated pep-
tides and subsequent activation of CTLs. The latter issue in
 
particular is of crucial importance for the understanding of
HSP-mediated cross-presentation, as antigen uptake by
APCs does not necessarily correlate with the ability to
cross-present antigens. Despite the fact that macrophages
and DCs phagocytose apoptotic cells, only immature DCs
are able to cross-present antigens and to activate CTLs (28).
Here, we demonstrate that members of the family of
professional APCs such as macrophages, DCs, and B cells
are able to bind the endoplasmic reticulum (ER)-resident
HSP gp96 specifically. The binding was saturable and could
be competed for with unlabeled gp96 molecules. The up-
take of gp96 isolated from cells expressing the adenovirus
type 5 (Ad5)-E1B epitope by the DC line D1 resulted in
the activation of E1B-specific CTLs. More importantly, ac-
tivation of Ad5-E1B–specific CTLs could be inhibited by
competition with gp96 not associated with E1B peptide.
This result clearly demonstrates that CTL activation is the
consequence of receptor-mediated endocytosis of gp96
molecules followed by the class I–restricted re-presentation
of associated peptides, and supports the participation of
HSPs in cross-presentation of cell-associated antigens.
 
Materials and Methods
 
Mice, Cells, Antibodies, and Proteins.
 
The DEC-205 knockout
mice were provided by Michel Nussenzweig and Ralph Stein-
man (The Rockefeller University, New York, NY). BALB/c
and C57BL/6 mice were obtained from Charles River Laborato-
ries. MHC class II–deficient mice ABBN5 (34) and littermate
ABBN6 were obtained from Taconic Farms. P388D1, RMA,
and RMA-S mouse cell lines (American Type Culture Collec-
tion) were cultured in 
 
a
 
-MEM. The cell line D2SC/1, repre-
senting an early progenitor of mouse splenic DC, and D1, a non-
transformed, growth factor–dependent, long-term DC culture
(35), were cultured in IMDM. All tissue culture media were sup-
plemented with 10% FCS, 0.3 mg/ml 
 
l
 
-glutamin, 100 U/ml
penicillin/streptomycin, and 50 
 
m
 
M 
 
b
 
-mercaptoethanol. To
grow D1 cells, medium was additionally supplemented with 30%
conditioned medium from the fibroblast cell line R1. Antibody
to gp96 (SPA-850) was obtained from StressGen Biotechnolo-
gies. The following labeled antibodies to mouse and human anti-
gens were obtained from BD PharMingen: H2-K
 
b
 
–biotin, H2-
A
 
b
 
–biotin, CD8-FITC, IFN-
 
g
 
–PE, CD16/CD32 (Fc block),
CD45R/B220-PE, CD19-PE, CD14-PE, CD90.2 (Thy1.2)-PE,
CD86 (B7.2)-PE, CD11c-PE, Mac-3–PE, CD1a-PE, CD83-PE,
and IgG1-PE and IgG2a-PE isotype controls. Goat anti–rabbit–
Alexa™ 546 and streptavidin-Alexa™ 546 (Molecular Probes)
were used as secondary reagents. BSA, biotinylated BSA, OVA,
and FITC were obtained from Sigma-Aldrich. Streptavidin-PE
was purchased from Jackson Laboratories. BSA and OVA were
labeled with FITC or biotin according to standard protocols.
Free FITC molecules were removed by reaction with Tris and
gel filtration through a Sephadex G-25 (Sigma-Aldrich) column.
gp96 and gp96-FITC from the mouse cell line IGELa2 were
provided by Immunosome. All animal studies were performed
according to our institutional guidelines and approved by our In-
stitutional Review Board.
 
Purification of gp96.
 
The transporter associated with antigen
processing (TAP)-deficient RMA-S SigE1B cell line has been
generated by transfection of RMA-S with the adenovirus early
 
1
 
Abbreviations used in this paper: 
 
Ad5, adenovirus type 5; BMDC, bone
marrow–derived dendritic cell; DC, dendritic cell; ER, endoplasmic
reticulum; gp, glycoprotein; HSP, heat shock protein; TAP, transporter
associated with antigen processing. 
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region 1 H2-D
 
b
 
–restricted E1B epitope (VNIRNCCYI) tar-
geted to the ER in a TAP-independent fashion (36). gp96 was
purified from RMA, RMA-S, and RMA-S SigE1B cell lines as
described (37). The approximate concentrations were deter-
mined by measuring the OD at 280 nm using an extinction coef-
ficient of 1.0.
 
Cytometry (FACS
 
®
 
) Binding Assay.
 
10
 
5
 
 cells were incubated
for 30 min on ice in 100 
 
m
 
l IMDM and 10% FCS containing 30
 
m
 
g/ml gp96-FITC or OVA-FITC, washed three times, and fixed
in 1% paraformaldehyde. For competition experiments, a given
excess of unlabeled gp96 was added together with 50 
 
m
 
g/ml
gp96-FITC simultaneously. For staining of mouse spleen cells (in-
cluding erythrocytes) and human PBLs, PE-conjugated antibodies
were added as markers for different cell types. Immature DCs
were prepared from bone marrow of C57BL/6 mice (38) and hu-
man blood monocytes (39) as described. Cytometry measure-
ments were performed on a FACSCalibur™ (Becton Dickinson).
 
Internalization Studies in Confocal Microscopy.
 
Immature bone
marrow–derived DCs (BMDCs) were prepared from C57BL/6
mice as described (38). On day 6 of their preparation, the BM-
DCs were tested for CD11c, CD86, and MHC class II expression
and were seeded on cover slips, precooled, and incubated for 30
min on ice with IMDM containing 10% FCS and 50 
 
m
 
g/ml
gp96-FITC (“pulse”). The coverslips were washed twice and in-
cubated in IMDM medium for 15 min or longer at 37
 
8
 
C
(“chase”), washed, and fixed in 3.7% paraformaldehyde in PBS.
For the colocalization experiments, cells were pre-incubated with
Fc block (
 
a
 
-CD16/CD32) followed by biotinylated antibodies to
H2-K
 
b
 
 or H2-A
 
b
 
 and 50 
 
m
 
g/ml gp96-FITC together with
streptavidin-Alexa™ 546. For staining of lysosomes, cells were
fixed with methanol/aceton (1:1, 
 
2
 
20
 
8
 
C) and incubated with
 
a
 
–Lamp-1 (provided by M. Fukuda, La Jolla Research Center,
La Jolla, CA) and goat anti–rabbit–Alexa™ 546. For microscopy, a
ZEISS LSM 510 laser scanning microscope was used. “Bleeding”
of emission into other detection channels was excluded using the
multitracking modus of the LSM 510. Thickness of the optical
plane was adjusted by the pinhole to be 
 
,
 
1 
 
m
 
m.
 
Immunization of Mice with gp96.
 
C57BL/6 mice were immu-
nized intraperitoneally with 30 
 
m
 
g gp96 purified from RMA-S
SigE1B cells. After 10 d, mice were killed and the spleen cells
were restimulated with E1B-expressing XC3 cells or Ad5-E1B
peptide (50 ng/ml). Specific lysis of RMA-S SigE1B cells by
CTLs contained in the spleen culture was determined by a
standard chromium release assay 5 d after restimulation and after
a second restimulation with XC3 cells or Ad5-E1B peptide (50
ng/ml).
 
CTL Cross-Presentation Assay.
 
The CTL clones 100B6, 0.1C2,
and LN5 were described previously (36, 40). CTL clones were
restimulated on a weekly basis by incubation with the Ad5-E1B/
E1A–expressing tumor cell line XC3. The E1B peptide was syn-
thesized on a ABI 432 A peptide snythesizer (Applied Biosystems)
applying Fmoc strategy.
Activation of CTL clones was assessed by measurement of in-
tracellular IFN-
 
g
 
 production. 2.5 
 
3 
 
10
 
4 
 
D1 cells were incubated
with 20 
 
m
 
g/ml gp96 purified from RMA-S SigE1B, RMA, or
RMA-S cells for 2 h at 37
 
8
 
C. For competition experiments, an
excess of gp96 from RMA or RMA-S was added, washed four
times, and incubated with 2.5 
 
3 
 
10
 
5 
 
CTLs for 12 h at 37
 
8
 
C. 10
 
m
 
g/ml Brefeldin A was added for an additional 5 h at 37
 
8
 
C. Cells
were washed, fixed, and perforated with saponin. The fixed cells
were stained with PE-labeled anti–IFN-
 
g
 
 or isotype control and
FITC-labeled anti-CD8 antibodies, and were measured by flow
cytometry.
 
Results
 
gp96 Binds Specifically to APC Lines.
 
Recent experiments
demonstrated that HSPs are able to interact specifically
with a macrophage- and a DC-like cell line (33). There-
fore, we further characterized the cell types able to interact
with gp96 in a specific manner. For this purpose, we incu-
bated several cell lines with FITC-labeled gp96, always
at 4
 
8
 
C to exclude endocytosis. We only observed a spe-
cific interaction of gp96 with APC lines like P388D1,
D2SC/1, and D1, but not with the lymphoma cell lines
RMA, EG.7, and T1 (Fig. 1, A and B). Increasing the total
concentration of gp96-FITC, the binding displayed satura-
tion at a total concentration of 30 
 
m
 
g/ml (Fig. 1 C) and
could only be competed for by unlabeled gp96, but not by
OVA (Fig. 1 A) or BSA (not shown). A onefold excess of
Figure 1. Specific binding of gp96-FITC to APC cell lines and BM-
DCs. Binding of 3 mg gp96-FITC to 105 D2SC/1 cells was performed,
always at 48C, in 100 ml IMDM containing 10% FCS. This binding could
be competed by a 10-fold excess of unlabeled gp96, but not OVA. (A)
Specific binding of gp96-FITC was observed on D2SC/1 (DC progeni-
tor), P388D1 (macrophage), and D1 (DC), but not on RMA and T1
cells. (B) Binding could be saturated at z30 mg/ml for 105 D2SC/1 cells
(C) and competed almost completely by a 100-fold excess of unlabeled
gp96. (D) Binding is given as relative values, where 100% represents max-
imum binding of gp96-FITC. The concentration values shown give total
concentration of gp96-FITC added to the cells. (E) Binding of 1 mg (bold
line), 5 mg (broken line), and 10 mg (dotted line) gp96-biotin/streptavi-
din-PE to immature BMDCs from C57BL/6 mice. (F) No binding was
observed for BSA-biotin/streptavidin-PE. Binding of 10 mg gp96-biotin
(bold line) to BMDC is competed in a similar fashion to D by unlabeled
gp96 (G), but not by unlabeled BSA (H). 
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unlabeled gp96 resulted in a 50% reduction, and a fivefold
excess resulted in an 
 
z
 
75% reduction of gp96-FITC bind-
ing at saturation point, which could be inhibited com-
pletely using an excess of up to a 100-fold (Fig. 1 D). These
data correspond to the theoretical values of 50% and 83%
(1:1 and 1:5 dilution of gp96-FITC with unlabeled gp96),
demonstrating that the FITC labeling of gp96 did not sig-
nificantly affect the binding characteristics to its putative re-
ceptor. No inhibition was observed using an excess of up
to 400-fold of OVA or BSA (data not shown). These data
demonstrate the presence of a specific gp96 receptor that
is expressed on APCs but not on other cell lines (Fig. 1,
A–D).
 
gp96 Interacts Specifically with Primary APCs in Mice and
Humans.
 
More importantly, gp96 (Fig. 1 E) but not BSA
(Fig. 1 F) bound efficiently to immature BMDCs prepared
(38) from C57BL/6 mice, and could be competed for by
increasing amounts of unlabeled gp96 (Fig. 1 G) but not by
BSA (Fig. 1 H). Specific binding was also observed when
mouse spleen cells from BALB/c mice were incubated
with gp96-FITC (Fig. 2). gp96 interacted specifically with
cells that stained positive for MHC class II and CD45
(B220), but not with cells positive for CD90 (Thy-1) mol-
ecules. Setting the forward and side scatter gate on the big-
ger cells, including cells of the myeloid lineage, CD11c–
and Mac-3–positive cells were also positive for gp96-FITC,
indicating that the expression of the gp96 receptor is re-
stricted to professional APCs. No staining was observed us-
ing OVA-FITC (Fig. 2, left) or BSA-FITC (data not
shown). The identical outcome was observed using spleen
cells from C57BL/6 mice (not shown). A similar gp96-
FITC staining pattern was obtained for human PBLs.
HLA-DR–, CD86-, CD19-, and CD14-positive but not
CD2- or CD3-positive cells interacted specifically with
gp96-FITC (Fig. 3 A). Again, no staining was observed us-
ing OVA-FITC. gp96 binding to monocytes was slightly
better than to B cells in human PBLs. As expected, DCs
expressing CD1a and CD83 were not detected. To deter-
mine gp96-FITC binding to this cell type, we differenti-
ated DCs from human PBLs by the application of GM-
CSF and IL-4. The whole DC population generated
stained positive with gp96 but not BSA (Fig. 3 B).
 
DEC-205 and MHC Class II Molecules Are Not Required
for gp96 Binding.
 
Because gp96 molecules contain a single
high-mannose oligosaccharide (41, 42), we addressed the
question of whether this might allow the uptake by the
DEC-205 receptor. DEC-205 is expressed on DCs and
thymic epithelial cells and is capable of directing captured
soluble exogenous antigens to a specialized antigen process-
ing compartment (43). DCs were prepared from bone mar-
row of wild-type and DEC-205
 
2
 
/
 
2
 
 mice (provided by
Michel Nussenzweig and Ralph Steinman) and incubated
with increasing amounts of gp96-FITC. FACS
 
®
 
 analysis
revealed identical staining (Fig. 4 A), suggesting that the
DEC-205 receptor is not involved in the binding of gp96
molecules by DCs.
We further speculated whether MHC class II might
function as a receptor for gp96 because gp96 showed bind-
ing to all MHC class II–positive mouse spleen cells and hu-
man PBLs. Binding together with marker antibodies to
spleen cells from MHC class II knockout mice and their lit-
termates did not reveal any difference (shown for MHC
class II antibody in Fig. 4 B; other markers not shown), in-
dicating that MHC class II molecules do not function as
gp96 receptors.
 
gp96 is Endocytosed Efficiently and Colocalizes with Recycled
MHC Class I and Class II Molecules.
 
Recently it has been
suggested that gp96-FITC bound to peritoneal macro-
phages is endocytosed into early endosomes but does not
reach the stage of lysosomes (44). We also attempted to de-
termine the faith of receptor-bound gp96 at the cell surface
of APCs by confocal microscopy (Fig. 5) using authentic
DCs (BMDCs from C57BL/6 mice). Initial binding of
Figure 2. Specific binding of gp96-FITC to B cells, macrophages, and
DCs, but not to T cells of a spleen cell culture. 105 fresh BALB/c spleen
cells were stained with 5 mg OVA-FITC (left) or gp96-FITC (right), and
different PE-labeled cell type marker antibodies to CD90.2 (Thy-1.2, T
cells), CD45R/B220 (B cells), I-Ad/Ed, CD11c (DCs), and Mac-3
(monocytes and macrophages). Macrophages and DCs were counted in a
different gate than lymphocytes with a higher forward scatter value. 
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FITC-labeled gp96 to the cell surface at 4
 
8
 
C to prevent en-
docytosis revealed a patched pattern. Further incubation at
37
 
8
 
C led to efficient endocytosis of gp96. Colocalization
with lysosomes labeled with Lamp-1 antibody (45) was not
observed after 15, 30, 45, 60, and 90 min of endocytosis
(shown for 60 min in Fig. 5). Recently, it has been re-
ported that internalized cell surface MHC class I molecules,
 
like class II molecules, are able to bind their antigen in en-
dosomal compartments, suggesting these vesicles to be pu-
tative MHC class I and class II loading compartments for
exogenously derived antigen (46). We therefore attempted
to determine whether gp96 taken up by receptor-mediated
endocytosis can be found in compartments containing re-
cycled MHC class I and class II molecules. Indeed, after 15
min of endocytosis, nearly all of the endocytosed H2-K
 
b
 
and H2-A
 
b
 
 molecules colocalized with gp96. Similar results
were obtained using gp96-FITC bound to the cell surface
of the D2SC/1 cell line, where after 15 min of endocytosis,
gp96 colocalized with transferrin Texas red (as marker for
early endosomes) and endocytosed H2-K
 
d
 
 molecules, but
were excluded from lysosomes after 30 min (data not
shown).
 
gp96-associated Peptides Are Loaded onto MHC Class I
Molecules as a Result of Receptor-mediated Endocytosis.
 
gp96
molecules have been observed to enter APCs by receptor-
mediated endocytosis as well as by non–receptor-mediated,
nonspecific endocytosis or macropinocytosis (33, 44). The
latter nonspecific pathways have been described many
times before to introduce exogenous proteins into the
MHC class I–restricted antigen pathway, but unlike recep-
tor-mediated endocytosis require high concentrations of
antigens (for a review, see reference 22).
To investigate whether receptor-mediated endocytosis
can lead to cross-presentation of gp96-associated antigens,
we have isolated gp96 from RMA-S SigE1B cells that sta-
bly express the H2-D
 
b
 
–restricted E1B epitope of Ad5,
fused with an ER-targeting signal sequence. C57BL/6
Figure 3. gp96-FITC binds to APCs in human PBL culture, but not to
T cells. (A) 105 fresh human PBLs were stained with 5 mg OVA-FITC
(left) or gp96-FITC (right) together with PE-labeled antibodies to the
following cell surface antigens: CD2 (T and NK cells), CD3 (T cells),
CD19 (B cells), CD86, HLA-DR, and CD14 (monocytes). The gate was
set on all living cells. Therefore monocytes appear as a population with a
slightly higher autofluorescence than lymphocytes in both fluorescence
channels. Comparing the shifts of each population, monocytes showed
slightly better binding of gp96 than B cells. (B) Binding of 0 mg (gray
shaded) and 5 mg (bold line) gp96-biotin to immature DCs prepared from
human PBLs. 10 mg of BSA-biotin (bold line) did not display binding.
Figure 4. DEC-205 and MHC class II do not function as receptors for
gp96. Binding of gp96-biotin to BMDCs from wild-type and DEC-
2052/2 mice (A) as well as binding of gp96-FITC to spleen cells from
MHC class II2/2 mice and their littermate (B) showed identical staining.
For staining of spleen cells in B, different cell surface markers were used
(shown in Fig. 2). Only antibody to MHC class II is shown. 
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mice immunized with these gp96 molecules generated
CTLs that recognized efficiently RMA-S SigE1B and
RMA cells pulsed with the Ad5-E1B peptide, but not
RMA cells, demonstrating the presence of the Ad5-E1B
epitope on gp96 molecules. Immunization with control
gp96 molecules from RMA-S cells did not induce Ad5-
E1B–specific CTL responses (Fig. 6).
To test whether the E1B epitope attached to gp96 was
re-presented to CTLs after uptake by APCs, gp96 isolated
from RMA-S SigE1B (or control gp96 from RMA-S cells)
was incubated with the DC cell line D1 for 2 h at 37
 
8
 
C.
The D1 cells were further incubated overnight with the
Ad5-E1B–specific CTL clones 100B6 and 0.1C2 or con-
trol CTL clone LN5, specific for the Ad5-E1A epitope. In-
tracellular IFN-
 
g
 
 production was measured to determine
CTL activation via the re-presentation of the Ad5-E1B
peptide. As shown in Fig. 7 A, incubation of 0.1C2 CTLs
with D1 cells pulsed with RMA-S SigE1B gp96 resulted in
the activation of T cells. This activation was not observed if
control gp96 isolated from RMA-S cells was used or if
gp96 isolated from RMA-S SigE1B cells was incubated
with the CTLs in the absence of D1 cells. The latter exper-
iment clearly demonstrates that D1 cells, which efficiently
bind gp96 molecules (shown in Fig. 1 B), are required for
the re-presentation. The T cells themselves are not able to
bind gp96 (shown in Figs. 2 and 3), and consequently do
not stimulate each other.
Most importanly, however, the activation of Ad5-E1B–
specific CTLs by gp96 from RMA-S SigE1B cells could be
inhibited by the addition of a twofold excess of irrelevant
gp96 molecules from RMA-S and RMA cells. This excess
of gp96 was able to reduce the binding of gp96-FITC by
60% (Fig. 1 D), and eliminated the activation of 0.1C2
CTLs by gp96 molecules from RMA-S SigE1B cells almost
Figure 5. gp96-FITC is endocytosed by BMDCs efficiently and colo-
calizes with endocytosed MHC class I and class II molecules, but does
not target to lysosomes. Internalization of gp96-FITC was followed by
confocal microscopy. Representative sections are displayed. Coverslip-
grown BMDCs were incubated with 50 mg/ml gp96-FITC (shown in
false color green) on ice, washed, chased for 15 min or longer at 378C,
and fixed in paraformaldehyde. To follow the fate of gp96-FITC after
15, 30, 45, 60, and 90 min (only 60 min is shown) of endocytosis, cells
were fixed and permeabilized with methanol/aceton and stained with
antibody to the Lamp-1 and secondary Alexa™ 546-coupled antibody to
visualize lysosomes (shown in false color red). No colocalization of gp96
and Lamp-1 was observed. Furthermore, cells were stained with biotiny-
lated antibodies to MHC class I (H2-Kb) and class II (H2-Ab) and sec-
ondary streptavidin-Alexa™ 546 (both shown in red) as well as gp96-
FITC (green) on ice, washed, and chased at 378C for 15 min. After 15
min of endocytosis, nearly all vesicles containing endocytosed gp96 and
MHC class I and class II molecules colocalize (shown in yellow as result
of overlapping green and red).
Figure 6. gp96–E1B complexes generate a CTL response in vivo. gp96
was purified from RMA-S SigE1B and RMA-S cells. 30 mg of gp96 from
either cell type was injected into C57BL/6 mice intraperitoneally. The
specificity of the generated CTLs was assayed by 51Cr-release of RMA-S
SigE1B cells (m), RMA cells incubated with 100 ng/ml Ad5-E1B pep-
tide (h), or RMA cells (d). The figure shows one representative of three
independent experiments.1971 Singh-Jasuja et al.
completely. The identical scenario was observed for a dif-
ferent Ad5-E1B–specific CTL clone, 100B6, but not for
LN5 CTLs, which are specific for the control Ad5-E1A
CTL epitope (Fig. 7 B). No competition was observed by
using a twofold excess of BSA as control (data not shown).
Discussion
HSPs have been shown previously to induce specific im-
mune responses against tumor, minor H, and viral antigens
(for reviews, see references 29 and 30). This feature is based
on peptides that are associated with HSPs and on the fact
that HSPs, by an unknown mechanism, can interact very
efficiently with APCs to result in the re-presentation of
HSP-associated peptides and subsequent activation of T
cells (31, 47). We have now shown in this study that spe-
cific binding of low amounts of gp96 to a receptor present
on mouse and human professional APCs is indeed required
for the MHC class I–restricted re-presentation of gp96-
associated peptides.
The nature of the gp96 receptor still remains unclear.
We reported earlier that gp96 binding to the macrophage
line P388D1 cannot be inhibited by mannan, thus arguing
against the participation of the mannose receptor. Using
DCs from DEC-2052/2 mice, we show here that this re-
ceptor as well, which displays strong homology to the
mannose receptor present on macrophages (43), is unlikely
to be involved, because gp96-FITC binding is indistin-
guishable from that observed for DCs of wild-type mice
(Fig. 4 A). Because DnaK and HSP73 molecules have been
reported to bind to certain allelic products of MHC class II
(48, 49), they could represent another potential receptor
for HSPs on the surface of APCs. The observation that
gp96 binds to all MHC class II–positive cells could indicate
that gp96 also uses MHC class II molecules as a receptor.
However, anti–MHC class II antibodies were not able to
inhibit the binding of gp96-FITC molecules (data not
shown), and cells from MHC class II2/2 mice showed
identical gp96 binding compared with wild-type mice, thus
arguing against MHC class II molecules being the receptor
for gp96 (Fig. 4 B).
We further demonstrate in this study that the specific in-
teraction of gp96 molecules with DCs results in re-presen-
tation of associated peptides and specific activation of
CTLs. gp96 molecules isolated from RMA-S SigE1B cells
that carry the Ad5-E1B CTL epitope (Fig. 6) are able to
activate Ad5-E1B–specific CTLs after incubation with the
DC line D1, as visualized by intracellular IFN-g staining.
The control CTL line LN5 is not activated by any of the
gp96 preparations tested (Fig. 7). More importantly, we are
able to show here for the first time that receptor-mediated
endocytosis of gp96 is indeed required for the re-presenta-
tion and subsequent activation of CTLs. By inhibiting the
specific binding of RMA-S SigE1B–derived gp96 with a
twofold excess of unrelated gp96 molecules that have been
shown to reduce gp96-FITC binding by 60% (Fig. 1 D),
we completely abolish the activation of Ad5-E1B–specific
CTLs (Fig. 5). This low excess of unrelated gp96 was cho-
sen on purpose to exclude potential toxic effects of a high
gp96 concentration. Using synthetic E1B peptide, z25%
of CTLs could be activated (data not shown), compared
with 6–7% activated CTLs, as shown in Fig. 7. Therefore,
the amount of RMA-S SigE1B gp96 was not able to acti-
vate all possible CTLs, most likely because of limiting
Figure 7. Specific activation of CTLs by DC-mediated cross-presenta-
tion of gp96-associated antigen requires receptor-mediated endocytosis of
gp96–antigen complexes. (A) Activation of Ad5-E1B–specific CTL clone
0.1C2 was assayed by intracellular IFN-g staining in flow cytometry. D1
DCs as APCs could activate the CTLs after prior incubation of D1 with
gp96–E1B complexes purified from RMA-S SigE1B (top left), but not
with irrelevant gp96 isolated from RMA-S (top right) or RMA cells (data
not shown) or in the absence of D1 cells (bottom right). Moreover, acti-
vation by gp96–E1B complexes could be competed with a twofold excess
of gp96 from RMA-S (bottom left) or RMA (not shown), but not with
the same excess of BSA (not shown), indicating the presence of a recep-
tor-mediated pathway responsible for processing of gp96 by D1 cells. PE-
labeled isotype control antibody was always negative (data not shown).
Results are representative for at least three experiments. (B) Summary of
the activation of Ad5-E1B–specific CTL clones 0.1C2 and 100B6 as well
as control CTL clone LN5 specific for Ad5 E1A. Graph shows the per-
centage of activated CTLs present in the gate shown in A. Addition of
Ad5–E1B peptide to D1 cells resulted in the activation of z25% of CTL
clones 0.1C2 and 100B6 (data not shown).1972 Receptor-mediated Cross-Presentation of HSP-associated Peptides
amounts of peptide. As the activation of CTLs requires the
activating signal to be above a certain threshold, the
amount of antigen presented by MHC class I molecules in
the presence of competitor could easily be below this
threshold, explaining the lack of a CTL response with a
twofold excess of irrelevant gp96 not associated with E1B
peptide.
Because only receptor-mediated endocytosis of labeled
gp96 but not nonspecific, non–receptor-mediated uptake
such as pinocytosis or macropinocytosis can be inhibited by
an excess of unlabeled gp96 (33), our results clearly dem-
onstrate that receptor-mediated endocytosis of gp96 mole-
cules is the cellular pathway responsible for re-presentation
of gp96-associated peptides by MHC class I molecules.
Therefore, our results provide evidence for the hypothesis
that professional APCs possess receptors that are able to in-
teract specifically with HSPs (32) and direct HSP-associated
peptides into the MHC class I–restricted antigen presenta-
tion pathway. This now explains why very small amounts
of gp96–peptide complexes can activate T cells.
The exact intracellular pathway for the re-presentation
of gp96-associated peptides requires further clarification.
Confocal microscopy data point in the direction that gp96
heads for early endosomes but does not enter lysosomes.
We could show that gp96 after receptor-mediated uptake
enters compartments containing MHC class I and class II
molecules. It can be speculated that these compartments
function as putative loading compartments where antigen
could be transferred to MHC class I and class II molecules
(46), but it cannot be excluded that gp96–antigen com-
plexes enter the cytosol specifically, as recently suggested
for immunoglobulin–antigen complexes after endocytosis
by Fc receptors in DCs (50).
Further identification of the pathway responsible for the
re-presentation of gp96-associated peptides will also con-
tribute to the understanding of the phenomenon termed
cross-presentation. Until now, cross-presentation of MHC
class I–restricted antigens has been shown to be induced by
receptor-mediated phagocytosis of apoptotic bodies (27,
28), exosomes (51), bacteria (52), and proteins, either dena-
tured or immobilized (26) by phagocytic or nonphagocytic
mechanisms (22). Unlike the latter two pathways, which in
most require cases high concentrations of the antigens, re-
ceptor-mediated endocytosis of HSPs operates efficiently at
antigen concentrations of z1–2 ng per mouse (31), and
might be as efficient as receptor-mediated phagocytosis of
apoptotic cells or receptor-mediated endocytosis of pro-
teins by surface immunoglobulins on B cells. One can en-
visage that HSPs, released from dying cells, bind to HSP
receptors of professional APCs and are endocytosed before
the associated peptides are re-presented by MHC class I
molecules.
The antigen carriers in apoptotic cells or exosomes are
unknown, but one interesting possibility is that HSPs chap-
erone the antigenic peptides, thus protecting them from
further degradation and directing them to the correct intra-
cellular loading compartment. In line with this speculation
is the observation that HSP70 is one of the proteins found
in close association with the transferrin receptor in exo-
somes derived from reticulocytes (53). Whether or not the
induction of apoptosis leads to a general increase of HSPs is
still controversial and might depend on factors that are still
to be determined. For tumor cells, it was reported that apop-
totic death was associated with low HSP expression levels
(54), whereas for PMNs, increased apoptosis coincided
with induction of Hsp72 (55). Nevertheless, an increase of
HSP expression levels generally seems to correlate with in-
creased immunogenicity (54, 56), supporting the above-
mentioned hypothesis.
The finding that cells deficient in TAP are still able to
cross-prime as efficiently as wild-type cells (57) does not
contradict the involvement of HSPs in cross-presentation.
It shows that the ER-resident HSP gp96 alone is not essen-
tial for cross-priming, but it also does not exclude the par-
ticipation of other HSPs such as HSP70 or HSP90 that
might compensate for the absence of immunogenic gp96–
peptide complexes. Another argument formulated against
the participation of HSPs in cross-presentation of cellular
antigens is based on an experiment performed by Carbone
and Bevan (58), in which splenocytes were incubated with
OVA or b-galactosidase, washed, and injected into mice.
Because of the nonspecific coating of cells with the soluble
proteins, an association with HSPs might be difficult to
imagine. However, the incubation conditions (378C, 10
mg/ml protein, 10 min), do not exclude the uptake and
processing of proteins and the subsequent loading of anti-
genic peptides onto HSPs. In addition, several different
pathways for cross-presentation, including apoptotic cells,
exosomes, and receptor-mediated endocytosis of HSPs,
might exist in parallel, each one able to induce the cross-
presentation of different types of antigens.
More detailed knowledge about the gp96 receptor, its
intracellular transport, and the regulation of expression in
different cell types will deepen our understanding of the
role of gp96 and possibly HSPs in general in cross-presen-
tation, and could greatly improve the application of gp96
for the induction of specific immune responses in vivo.
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